Australian Technology Innovation Fund Limited Your entry into the lucrative biotech market Australian Technology Innovation Fund Limited Prospectus presentation Your entry into the lucrative biotech market

Australian Technology Innovation Fund Limited Your entry into the lucrative biotech market The biotech market Biotechnology is a highly specialised sector offering excellent investment opportunities to those able to identify projects with global commercialisation potential. ATIF identifies and develops biotechnology projects of the highest potential in Australia and offshore. This is your opportunity to own a share of the lucrative biotech market.

Australian Technology Innovation Fund Limited Your entry into the lucrative biotech market The biotech market Traditionally, there is a lack of suitable entities in the biotech market with: –The complex skills required to target appropriate biotechnology investments –The ability to cost-effectively manage the risk profile of a specialised biotechnology portfolio. ATIF has the experienced management and complex skills required for success in this field.

Australian Technology Innovation Fund Limited Your entry into the lucrative biotech market About ATIF ATIF holds an attractive and diverse asset base through its interests in three Australian biotechnology companies: –CBio Limited (16.37%) –Psiron Limited (15.93%) –Analytica Limited (14.71%) ATIF provides assistance to these companies to achieve their commercial objectives.

Australian Technology Innovation Fund Limited Your entry into the lucrative biotech market About ATIF Directors –Dr Wolf Hanisch – more than 20 years experience in the biotech industry, including a $45 million IPO for Idec Pharmaceuticals. –Mr Stephen Jones – corporate recovery and turnaround specialist. Former member of Qld Govt’s Queensland Innovation Council.

Australian Technology Innovation Fund Limited Your entry into the lucrative biotech market About ATIF Directors cont… –Dr Michael Monsour – medical practitioner with business interests in QLD medical centres. ATIF has specialist expertise in biotechnology and capital financing sectors – a key ATIF advantage.

Australian Technology Innovation Fund Limited Your entry into the lucrative biotech market About ATIF ATIF’s Board and Management have high-level scientific and financial experience and are intending ATIF to become Australia’s leading diversified biotechnology company. ATIF intends to retain its focus on biotechnology investment, and has formulated the following business plan.

Australian Technology Innovation Fund Limited Your entry into the lucrative biotech market ATIF Business Plan 1.Fulfil own working capital needs from revenues raised through specialist corporate advisory to biotech sector. 2.Effective ongoing management of existing interests. 3.Assisting ATIF investments in achieving product development and funding outcomes.

Australian Technology Innovation Fund Limited Your entry into the lucrative biotech market ATIF Business Plan 4.Identifying new investment opportunities and industry alliances both in Australia and overseas. 5.Integrating acquisitions and developing well-timed “spin off” IPO opportunities. The ATIF Business Plan gives a clear path for success in the biotech sector.

Australian Technology Innovation Fund Limited Your entry into the lucrative biotech market ATIF’s Investments ATIF has stringent criteria used in selecting current and future investments: –Product-focussed investment approach –Risk management –Technical competence and skilled hands-on management –IP protection and product-base diversification

Australian Technology Innovation Fund Limited Your entry into the lucrative biotech market ATIF’s Investments ATIF’s investments are diversified among a variety of complementary biotech areas: –CBio Ltd Immune System modulation –Psiron Ltd Anti-inflammation, Anti-cancer –Analytica Ltd Diagnostics

Australian Technology Innovation Fund Limited Your entry into the lucrative biotech market CBio Ltd Unlisted Australian Public Company who owns patent for hormone Early Pregnancy Factor (EPF). EPF has patented applications in: –auto-immune disease market (MS and R. Arthritis) –organ rejection –burns treatment –cancer (diagnosis and therapy) –being prepared for listing “04-05” on appropriate international exchange.

Australian Technology Innovation Fund Limited Your entry into the lucrative biotech market Psiron Ltd Australian Public Company which listed on ASX. Operates in biotech/healthcare segment and has investments in –Analytica Ltd. –CBio

Australian Technology Innovation Fund Limited Your entry into the lucrative biotech market Psiron Ltd Therapeutics interests are in anti-cancer and anti- inflammation such as: –SPLA2 anti-inflammation New generation anti-inflammatory –Psorafin psoriasis Psiron owns worldwide rights to the patented Sorafin compound (treatment for Psoriasis) under and exclusive license. Psoriasis is one of the world’s most common skin diseases.

Australian Technology Innovation Fund Limited Your entry into the lucrative biotech market Analytica Ltd Australian public company listed on the ASX. Diagnostics business with current annual sales revenues of approximately $1.2 million.

Australian Technology Innovation Fund Limited Your entry into the lucrative biotech market The ATIF advantage Established to take advantage of value-priced investment opportunities in the biotechnology sector, ATIF offers industry-specific expertise and an established and diverse portfolio of biomedical projects and patents.

Australian Technology Innovation Fund Limited Your entry into the lucrative biotech market The ATIF advantage ATIF has the specialist expertise to surmount traditional biotech investment barriers. ATIF fills a void in the investment sector.

Australian Technology Innovation Fund Limited Your entry into the lucrative biotech market The ATIF share offer 5 million fully-paid shares in ATIF Ltd are on offer at an issue price of $1.00 each. Minimum requirement 2000 shares at $1.00 per share, or greater numbers in multiples of 1000 thereafter. Applications accepted from 23 October 2002 until 20 December 2002.

Australian Technology Innovation Fund Limited Your entry into the lucrative biotech market The ATIF share offer Why Invest in ATIF? –Excellent capital growth opportunities –Exclusive preferential access to additional investment opportunities, including underwriting and sub- underwriting agreements, IPOs and other share issues –The benefit of diversification in the biotechnology sector

Australian Technology Innovation Fund Limited Your entry into the lucrative biotech market The ATIF share offer By investing in ATIF, shareholders: –Gain ownership of an excellent capital growth opportunity –Gain access to key “deal maker” positions resulting from ATIF initiatives

Australian Technology Innovation Fund Limited Your entry into the lucrative biotech market Your opportunity This is your opportunity to invest in an attractive and diverse biotechnology asset base, and benefit from: –Diversity through ATIF’s four investments for price of one –Low entry price for new investments –Strong Board and Management team with real experience

Australian Technology Innovation Fund Limited Your entry into the lucrative biotech market Your opportunity Further information for your perusal: –Prospectus for Australian Technology Innovation Fund Limited share offer

Australian Technology Innovation Fund Limited Your entry into the lucrative biotech market Your questions answered If you have any questions or would like a copy of the complete prospectus, contact us at ATIF on: Ph Fax PO BX 3104 South Brisbane BC QLD 4101 Australia

Australian Technology Innovation Fund Limited Your entry into the lucrative biotech market Your entry into the lucrative biotech market